Integer Holdings Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Integer Holdings Corporation
Private Company Edition: The astonishing pace of venture capital investment in drug development continues with another $1.5bn in financings of $100m or more, including $152m for Pyxis and $126m for Omega. New VC funds also continue to launch, including RiverVest’s fifth fund, totaling $275m.
Private Company Edition: Venture capital mega-rounds continue a brisk pace with machine learning-based drug discovery firm insitro and gene therapy developer Graphite Bio among recent $100m-plus deals. Also, Argobio raised €50m to fund five start-ups in Europe.
Public Company Edition: The former Allergan CEO is taking a special purpose acquisition corporation public to generate $460m for deals in familiar biopharma niches. Also, IPOs are expected to keep up a robust pace in the fall and Albireo raises $160m on the success of its drug for pediatric liver diseases.
BIO 2020 Notebook: FDA's Hahn On COVID-19 Lessons To Be Learned; NIH's Fauci On Health Care Disparities; Pfizer's Young On Forgoing Gov't Vaccine Funds
News and views from day three of BIO Digital. US FDA Commissioner Hahn asks industry to help identify best regulatory lessons from the pandemic; Pfizer’s chief business officer explains how need to move quickly in vaccine partnership with BioNTech led to decision to forgo US funding.
- Medical Devices
- Implantable Devices
- Surgical Equipment & Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
- CCC Medical Devices
- Greatbatch, Inc.
- InoMec Ltd.
- Lake Region Medical Holdings, Inc.
- NeuroNexus Technologies
- Quan Emerteq LLC
- US BioDesign, LLC